RxSight
RXST
39 hedge funds and large institutions have $100M invested in RxSight in 2021 Q3 according to their latest regulatory filings, with 39 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
29% more ownership
Funds ownership: 0% → 29% (+29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$42M |
| 2 |
O
OrbiMed
New York
|
+$17.2M |
| 3 |
DM
Deerfield Management
New York
|
+$12.4M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$7.02M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.61M |
Top Sellers
RXST Hedge Fund Activity: Q3 2021 in Review
39 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in RxSight (RXST) for Q3 2021, worth a combined $100M.
Buyers outnumbered sellers: 39 funds opened new RXST positions and 0 closed out — a net gain of 39 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $42M.
- 39 institutional investors held RxSight (RXST) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $100M of RxSight stock for Q3 2021.
- 39 funds opened new RxSight positions in Q3 2021 and 0 closed out, a net change of +39 holders.
- The largest RxSight buyer in Q3 2021 was RA Capital Management, an estimated $42M added.
Based on aggregated 13F filings for Q3 2021.